HIV Infection and Bone Abnormalities.

Area of Science:

• Bone Metabolism and HIV Research
• Pharmacology of Antiretroviral Therapy

Background:

• Over 36 million people live with HIV globally, with 50% on antiretroviral therapy (ART).
• ART has improved HIV management but is linked to bone abnormalities like low bone mineral density (BMD), osteoporosis, and fractures.
• HIV protease inhibitors and tenofovir formulations are associated with increased bone density loss.

Purpose of the Study:

• To investigate the relationship between HIV, ART, and bone health.
• To explore the impact of different ART regimens on bone mineral density (BMD).
• To identify potential interventions to mitigate bone loss in HIV-infected individuals.

Main Methods:

• Review of existing literature on HIV, ART, and bone metabolism.
• Analysis of studies comparing different antiretroviral agents and their effects on BMD.
• Examination of the role of HIV infection and ART components in bone cell function.

Main Results:

• HIV protease inhibitors and certain tenofovir formulations are associated with higher rates of osteopenia, osteoporosis, and low BMD.
• Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) has shown improvement in BMD.
• ART regimens including integrase inhibitors are linked to better BMD outcomes.

Conclusions:

• HIV and ART contribute to bone abnormalities through complex interactions involving immune cells and bone cells.
• Specific ART modifications, such as TAF and integrase inhibitors, may improve BMD in HIV patients.
• Vitamin D and calcium supplementation alongside ART initiation could help prevent bone loss and should be monitored.